BioPharmSignal logoBioPharmSignal

Biotech News

Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results

Mineralys Therapeutics (MLYS)Mineralys TherapeuticsFDA / regulatory

MLYS (MLYS) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is mlys.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

MLYSMineralys Therapeutics2026-05-30 15:15 EST

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

MLYSMineralys Therapeutics2026-05-18 20:05 EST

Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

ALGSAligos Therapeutics2026-04-14 20:05 EST

Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation

VANIVivani Medical2026-06-25 11:30 EST

Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management

VKTXViking Therapeutics2026-06-11 11:05 EST

Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer

MNKDMannKind2026-05-29 16:30 EST

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

TERNTerns Pharmaceuticals2026-04-27 12:05 EST

Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia

MNKDMannKind2026-01-26 11:05 EST

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy

NAMSNewAmsterdam Pharma2026-01-09 13:00 EST

NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities

VKTXViking Therapeutics2026-06-24 11:05 EST

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

View all latest news

Mineralys Therapeutics

Mineralys Therapeutics is a cardiometabolic company focused on aldosterone biology and hypertension-related opportunities. Its story is tied to differentiating a novel mechanism in a large market.

Recent company news

MLYSMineralys Therapeutics2026-07-27 20:01 EST

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

MLYSMineralys Therapeutics2026-06-14 14:00 EST

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

MLYSMineralys Therapeutics2026-06-08 20:05 EST

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

MLYSMineralys Therapeutics2026-06-08 11:00 EST

Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)

MLYSMineralys Therapeutics2026-06-03 10:05 EST

Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

Stock data

Close
27.21 USD
Market cap
2.38B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States